序号股东名称持股比例1上海君实生物医药科技股份有限公司100% 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；货物进出口；技术进出 口；信息咨询服务（不含许可类信息咨询服务）。（除依法须经批准的项目外，凭营业执照依法自主开 展经营活动） 天眼查显示，近日，上海君亦乐生物科技有限公司成立，法定代表人为谢皖，注册资本50000万人民 币，由上海君实生物医药科技股份有限公司全资持股。 企业名称上海君亦乐生物科技有限公司法定代表人谢皖注册资本50000万人民币国标行业科学研究和技 术服务业>科技推广和应用服务业>技术推广服务地址中国（上海）自由贸易试验区临港新片区新杨公 路860号10幢企业类型有限责任公司（非自然人投资或控股的法人独资）营业期限2026-1-20至无固定期 限登记机关自由贸易试验区临港新片区市场监管局 来源：市场资讯 ...

Core Viewpoint - China Biotechnology Services (08037) has entered into a subscription agreement with Fucai Holdings to issue convertible bonds worth $35 million, equivalent to approximately HKD 272.3 million, aimed at strengthening the company's capital base and financial position [1] Group 1: Convertible Bonds Issuance - The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million [1] - The initial conversion price is set at HKD 0.66 per share, which is subject to adjustment [1] - If the conversion rights attached to the bonds are fully exercised, up to 412.6 million shares will be issued, representing approximately 42.28% of the total shares currently in issue [1] Group 2: Impact on Shareholders - The issuance of convertible bonds will not cause immediate dilution of existing shareholders' equity [1] - If the conversion rights are exercised, the total number of shares issued will increase by approximately 29.72%, assuming no changes in the company's issued share capital from the announcement date until conversion [1] Group 3: Investor Profile - The subscriber, Fucai Holdings, primarily engages in investment activities across various sectors, including life sciences, education, internet, technology media, and telecommunications, managing assets exceeding $100 million [1] Group 4: Strategic Rationale - The board believes that the subscription will enhance the company's capital foundation, preparing for long-term development and improving financial conditions [1] - The issuance of convertible bonds is seen as an opportunity to expand and strengthen the capital base while attracting new investors to broaden the shareholder base [1]

Core Viewpoint - China Biotechnology Services (08037.HK) has entered into a subscription agreement with Fucheng Holdings Limited for the issuance of convertible bonds totaling $35 million, equivalent to approximately HKD 272.3 million, with a conversion price set at HKD 0.66 per share, representing a discount of about 16.46% from the closing price of HKD 0.79 on the agreement date [1] Group 1 - The total principal amount of the convertible bonds is $35 million, which will result in a maximum issuance of approximately 413 million shares, accounting for about 42.28% of the total shares outstanding as of the announcement date [1] - The net proceeds from the issuance of the convertible bonds are expected to be approximately $33.9 million [1] - The company plans to allocate 47.6% of the net proceeds for repaying other loans' principal and interest [1] Group 2 - 25.8% of the net proceeds will be used for the development and construction of a network of boron neutron capture therapy centers for cancer treatment [1] - 5.7% of the net proceeds will be allocated for research and development costs [1] - 20.9% of the net proceeds will be utilized for general working capital purposes [1]

Core Insights - Shanghai Muyuan Chunsheng Biotechnology Co., Ltd. has been established with a registered capital of 500,000 RMB [1] - The company is engaged in a variety of services including technology services, health consulting, and management consulting [1] Company Overview - The legal representative of the company is Zhu Rui [1] - The business scope includes technology development, consulting, and transfer, as well as health consulting services excluding medical diagnosis [1] - Additional services offered include information technology consulting, social and economic consulting, engineering management, patient companionship, and sales of cosmetics and daily necessities [1] Business Activities - The company is authorized to conduct business activities autonomously based on its business license, excluding projects that require approval [1] - The company also engages in the wholesale and retail of cosmetics, internet sales (excluding licensed products), and sales of sanitary and disposable medical supplies [1]

Core Points - Recently, Kunming Quanlai Biotechnology Co., Ltd. was established with a registered capital of 1 million RMB [1] - The legal representative of the company is Lin Shangjun [1] - The business scope includes licensed projects such as beauty services, medical beauty services, and fertilizer production [1] Business Scope - Licensed Projects: - Life beauty services - Medical beauty services - Fertilizer production [1] - General Projects: - Technical services, development, consulting, exchange, transfer, and promotion - Fertilizer sales - Research and development of biological organic fertilizers - Chemical fertilizer sales - Mixed processing of soil and fertilizers - Nail services - Import and export of goods - Import and export of technology - Import and export agency - Wholesale of computer software, hardware, and auxiliary equipment - Information system integration services [1]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $104.6 million, reflecting a 10% year-over-year growth [4][14] - Adjusted EBITDA for Q3 was $35.2 million, with a margin of 34% [4][18] - Q3 bookings totaled $96.6 million, representing a 1% increase year-over-year [5][14] - The company narrowed its revenue guidance for 2025 to $415-$420 million, indicating 8%-9% growth compared to 2024 [5][20] Business Line Data and Key Metrics Changes - Software revenue reached $43.8 million, growing 22% year-over-year, with organic growth of 6% [10][15] - Service revenue was $60.8 million, up 3% year-over-year, driven by growth in QSP services [11][17] - Software bookings of $40.8 million increased 17%, while service bookings declined 9% [10][17] Market Data and Key Metrics Changes - Tier 1 services customers exhibited cautious spending behavior, impacting deal timelines [5][6] - The adoption of biosimulation solutions is increasing among large pharma customers, particularly in model-informed drug development [6][8] Company Strategy and Development Direction - The company is focused on investing in R&D and commercial teams, with R&D spending up 24% year-over-year [4][11] - Certara is expanding its software capabilities into discovery and preclinical phases, enhancing its product offerings [9][30] - The strategic review of the regulatory services business is nearing completion, with a definitive outcome expected by the end of 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in deal completion timelines, particularly in regulatory services, due to large pharma customers adjusting their R&D focus [6][12] - There are positive leading indicators for the biosimulation market, with expectations for continued growth in 2026 [6][20] - Management expressed cautious optimism regarding macroeconomic stability and its potential positive impact on customer spending [35][46] Other Important Information - The company completed the Chemaxon acquisition, which has contributed positively to revenue and is expected to reach corporate average margins by year-end [9][19] - The company has repurchased approximately $41 million of stock as part of a $100 million share repurchase program [19] Q&A Session Summary Question: What is the dynamic regarding tier one services revenue or bookings? - Management noted delays in decision-making among tier one customers, with expectations for some deals to close in Q4 and others pushed to 2026 [23][24] Question: Can you comment on the gross profit outperformance? - Management attributed gross margin improvement to productivity gains and a favorable mix shift towards software [25][26] Question: How is the growth of QSP expected to evolve? - The company aims to standardize QSP modeling through its new software platform, Certara IQ, which is expected to drive efficiency and financial benefits [27][30] Question: What is the outlook for tier two and tier three services? - Tier two and tier three services have shown good growth, partially offsetting the headwinds faced by tier one services [64][65] Question: How does the company view the impact of AI on its business? - Management sees AI as a significant opportunity, with increased willingness among customers to adopt AI-enabled products [41][42]

Group 1 - The core point of the news is that Aopumai's stock price has decreased by 5.02%, currently trading at 55.87 CNY per share, with a total market capitalization of 6.359 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with product revenue accounting for 87.34% and service revenue for 12.53% [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Aopumai, with its Guotai National Policy Driven Flexible Allocation Mixed A Fund holding 3,140 shares, representing 0.65% of the fund's net value [2] - The Guotai National Policy Driven Flexible Allocation Mixed A Fund has a total scale of 21.707 million CNY and has achieved a year-to-date return of 3.97% [2] - The fund manager, Deng Shifeng, has a tenure of 17 years and has achieved the best fund return of 167.36% during his management period [2]

Meeting Overview - The fourth board meeting of Shanghai Univi Technology Co., Ltd. was held on September 28, 2025, with all nine directors present [2][4]. - The meeting was chaired by Chairman Leng Zhaowu, and it complied with legal and regulatory requirements [2]. Resolutions Passed - The board approved the reappointment of Lixin Zhonglian Certified Public Accountants as the auditing firm for the fiscal year 2025, with a one-year term [3][5]. - The voting results for this resolution were 9 votes in favor, 0 against, and 0 abstentions [4]. Amendments to Company Regulations - The board approved amendments to the company's articles of association and related rules to align with new regulations from the China Securities Regulatory Commission [6][8]. - The voting results for this resolution were also 9 votes in favor, 0 against, and 0 abstentions [7]. Institutional Revisions - The board reviewed and approved multiple revisions to internal governance documents, including the management of fundraising, independent director work, and related party transactions [9][10]. - Each of these revisions received unanimous support with 9 votes in favor, 0 against, and 0 abstentions [11]. Upcoming Shareholder Meeting - The board agreed to convene the third extraordinary general meeting of shareholders on October 16, 2025, combining on-site and online voting methods [22][23]. - The meeting will address the resolutions passed in the board meeting and will require a two-thirds majority for special resolutions [54].

Core Viewpoint - China Biotechnology Services (08037.HK) reported a significant improvement in financial performance for the six months ending June 30, 2025, with a revenue increase of 19.8% year-on-year, indicating effective cost control measures and compensation income from insurance claims [1] Financial Performance - Revenue reached HKD 38.872 million, up 19.8% compared to the previous year [1] - Gross profit was HKD 2.542 million, a recovery from a gross loss of HKD 3.107 million in the same period last year [1] - The loss attributable to owners of the company was HKD 32.006 million, a significant reduction of 60.0% from HKD 79.917 million in the prior year [1] - Basic loss per share was HKD 0.033 [1] Operational Improvements - The improvement in operational performance was primarily due to successful implementation of cost control measures, leading to an increase in gross margin and a reduction in administrative expenses [1] - The company received approximately HKD 13.7 million in compensation income related to damages from heavy rainfall affecting construction sites in Hainan during 2024 [1]

Core Insights - China Biotechnology Services (08037) reported a mid-year revenue of HKD 38.872 million for 2025, representing a year-on-year increase of 19.79% [1] - The company recorded a loss attributable to shareholders of HKD 32.006 million, which is a reduction of 59.95% compared to the previous year [1] - The loss per share is HKD 0.033 [1] Financial Performance - Revenue for the first half of 2025 reached HKD 38.872 million, showing a growth of 19.79% year-on-year [1] - The loss attributable to shareholders decreased significantly by 59.95%, amounting to HKD 32.006 million [1] - The earnings per share were reported at HKD 0.033 [1] Key Factors for Improvement - The improvement in loss is primarily attributed to successful cost control measures implemented by the company, which led to an increase in gross margin and a reduction in administrative expenses [1] - The company received compensation income of approximately HKD 13.7 million related to insurance claims for damages caused by heavy rainfall affecting construction sites in Hainan in 2024 [1]